The chemokine network in systemic lupus erythematous nephritis

Frontiers in Bioscience

Volumn 13, Issue 3, 2008, Pages 904-922

  Rovin, Brad H ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmunity; Chemokine; Chemokine receptors; Glomerulonephritis; Inflammation; Review; Systemic lupus erythematosus

Indexed keywords

ANIMALIA;

CHEMOKINE; MESSENGER RNA; NFE2L2 PROTEIN, HUMAN; PROSTAGLANDIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; GENOTYPE; HUMAN; INFLAMMATION; METABOLISM; MOUSE; NEPHRITIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANIMALS; CHEMOKINES; DISEASE MODELS, ANIMAL; GENOTYPE; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MODELS, BIOLOGICAL; MODELS, GENETIC; NEPHRITIS; NF-E2-RELATED FACTOR 2; PROSTAGLANDINS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 38449098287     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2731     Document Type: Review

References (157)

1. Labowitz, R. & H. R. Schumacher: Articular manifestations of systemic lupus erythematosus. Ann. Int. Med., 74, 911-921 (1971)
2. Tsokos, G. C., H. M. Moutsopoulos & A. D. Steinberg: Muscle involvement in systemic lupus erythematosus. JAMA, 246, 766-768 (1981)
3. Doherty, N. E. & R. J. Siegel: Cardiovascular manifestations of systemic lupus erythematosus. Am. Heart J., 110, 1257-1265 (1985)
4. Quismorio, F. P.: Clinical and pathologic features of lung involvement in systemic lupus erythematosus. Semin. Resp. Dis., 9, 297-304 (1988)
5. Weinrib, L., O. P. Sharma & F. P. Quismorio: A long term study of interstitial lung disease in systemic lupus erythematosus. Semin. Arthritis Rheum., 16, 479-481 (1990)
6. Johnson, R. T.: Neurologic and neuropathologic observations in lupus erythematosus. N. Engl. J. Med., 266, 895-900 (1962)
7. Johnson, R. T. & E. P. Richardson: The neurological manifestations of systemic lupus erythematosus. A clinical-pathological study of 24 cases and review of the literature. Medicine, 47, 337-369 (1968)
8. Castiglione, A., A. Bucci, G. Fellin, G. d'Amico & R. C. Atkins: The relationship of infiltrating renal leukocytes to disease activity in lupus and cryoglobulinaemic glomerulonephritis. Nephron, 50, 14-21 (1988)
9. Park, M. H., D. D'Agati, G. B. Appel & C. L. Pirani: Tubulointerstitial disease in lupus nephritis: Relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron, 44, 309-314 (1986)
10. Hill, G. S.: Systemic lupus erythematosus and mixed connective tissue disease. In: Pathology of the Kidney. Ed: R. H. Heptinstall. Little, Brown and Co., Boston (1992)
11. Srebrow, A., A. F. Muro, S. Werbajh, P. A. Sharp & A. R. Kornblihtt: The CRE-binding factor ATF-2 facilitates the occupation of the CCAAT box in the fibronectin gene promoter. FEBS Lett., 327, 25-28 (1993)
12. Kelley, V. E., S. Sneve & S. Musinski: Increased renal thromboxane production in murine lupus nephritis. J. Clin. Invest., 77, 252-259 (1986)
13. Spurney, R. F., P. Ruiz, D. S. Pisetsky & T. M. Coffman: Enhanced renal leukotriene production in murine lupus: Role of lipoxygenase metabolites. Kidney Int., 39, 95-102 (1991)
14. Boswell, J. M., M. A. Yui, D. W. Burt & V. E. Kelley: Increased tumor necrosis factor and IL-1 gene expression in the kidneys of mice with lupus nephritis. J. Immunol., 141, 3050-3054 (1988)
15. Cole, E. H., M. F. X. Glynn, C. A. Laskin, J. Sweet, N. Mason & G. A. Levy: Ancrod imporves survival in murine lupus erythematosus. Kidney Int., 37, 29-35 (1990)
16. Lovett, D. H., J. L. Ryan & R. B. Steizel: Stimulation of rat mesangial cell proliferation by macrophage IL-1. J. Immunol., 131, 2830-2836 (1983)
17. Ozen, S., U. Saatci, K. Tinaztepe, A. Bakkaloglu & A. Barut: Urinary tumor necrosis factor levels in primary glomerulopathies. Nephron, 66, 291-294 (1994)
18. Sedor, J. R., Y. Nakazato & M. Konieczkowski: Interleukin-1 and the mesangial cell. Kidney Intl., 41, 595-599 (1992)
19. Torbohm, I., B. Berger, M. Sconermark, J. Von Kempis, K. Rother & G. M. Hansch: Modulation of collagen synthesis in human glomerular epithelial cells by interleukin-1. Clin. Exp. Immunol., 75, 427-431 (1989)
20. Gallo, C. D., A. M. Jevnikar, D. C. Brennan, S. Florquin, A. Pacheco-silva & V. R. Kelley: Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int., 42, 851-859 (1992)
21. Austin, H. A., III, D. T. Boumpas, E. M. Vaughan & J. E. Balow: Predicting renal outcomes n severe lupus nephritis: Contribution s of clinical and histologic data. Kidney Int., 45, 544-550 (1994)
22. D'Agati, V. D., G. B. Appel, D. Estes, D. M. Knowles & C. L. Pirani: Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int., 30, 573-581 (1986)
23. Alexopoulos, E., D. Seron, R. B. Hartley & J. S. Cameron: Lupus nephritis: Correlation of interstitial cells with glomerular function. Kidney Int., 37, 100-109 (1990)
24. Rovin, B. H., L. Lu & C. B. Marsh: Lymphocytes induce monocyte chemoattractant protein-1 production by renal cells after Fcgamma receptor cross-linking: role of IL-1beta. J. Leuk. Biol., 69, 435-439 (2001)
25. Marsh, C. B., M. D. Wewers, L. C. Tan & B. H. Rovin: FcgammaR cross-linking induces peripheral blood mononuclear cell MCP-1 expression: Role of lymphocyte FcgammaR III. J. Immunol., 158, 1078-1084 (1997)
26. Marsh, C. B., M. P. Lowe, B. H. Rovin, J. M. Parker, Z. Liao, D. L. Knoell & M. D. Wewers: Lymphocytes produce IL-1B in response to Fc gamma receptor crosslinking: Effects on parenchymal cell IL-8 release. J. Immunol., 160, 3942-3948 (1998)
27. Marsh, C. B., C. L. Anderson, M. P. Lowe & M. D. Wewers: Monocyte IL-8 release is induced by two independent Fc gamma R-mediated pathways. J. Immunol., 157, 2632-2637 (1996)
28. Nelson, P. J. & A. M. Krensky: Chemokines, lymphocytes and viruses: what goes around, comes around. Curr. Opin. Immunol., 10, 265-270 (1998)
29. Perez de Lema, G., H. Maier, E. Nieto, V. Vielhauer, B. Luckow, F. Mampaso & D. Schlondorff: Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J. Am. Soc. Nephrol., 12, 1369-1382 (2001)
30. Liu, J., G. Karypis, K. L. Hippen, A. L. Vegoe, P. Ruiz, G. S. Gilkeson & T. W. Behrens: Genomic view of systemic autoimmunity in MRL/lpr mice. Genes Immunity, 7, 156-168 (2006)
31. Ishikawa, S., T. Sato, M. Abe, S. Nagai, N. Onai, H. Yoneyama, Y. Zhang, T. Suzuki, S. Hashimoto, T. Shirai, M. Lipp & K. Matsushima: Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J. Exp. Med., 193, 1393-1402 (2001)
32. Nozaki, Y., T. Yamagata, B.-S. Yoo, M. Sugiyama, S. Ikoma, K. Kinoshita, M. Funauchi & A. Kanamaru: The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF1 mice. Clin. Exp. Immunol., 139, 74-83 (2005)
33. Qing, X., J. Zavadil, M. B. Crosby, M. P. Hogarth, B. H. Hahn, C. Mohan, G. S. Gilkeson, E. P. Bottinger & C. Putterman: Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum, 54, 2198-2110 (2006)
34. Tesch, G. H., S. Maifert, A. Schwarting, B. J. Rollins & V. R. Kelley: Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-faslpr mice. J. Exp. Med., 190, 1813-1824 (1999)
35. Zoja, C., D. Corna, G. Benedetti, M. Morigi, R. Donadelli, A. Gugliemotti, M. Pinza, T. Bertani & G. Remuzzi: Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int., 53, 726-734 (1998)
36. Hasegawa, H., M. Kohno, M. Sasaki, A. Inoue, M. R. Ito, M. Terada, K. Hieshima, H. Maruyama, J.-I. Miyazaki, O. Yoshie, M. Nose & S. Fujita: Antagonist of monocyte chemoattractant protein-1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum, 48, 2555-2566 (2003)
37. Shimizu, S., H. Nakashima, K. Masutani, Y. Inoue, K. Miyake, M. Akahoshi, Y. Tanaka, K. Egashira, H. Hirakata, T. Otsuka & M. Harada: Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatol., 43, 1121-1128 (2004)
38. Perez de Lema, G., H. Maier, T. J. Franz, M. Escribese, S. Chilla, S. Segerer, N. Camarasa, H. Schmid, B. Banas, S. Kalaydjiev, D. H. Busch, K. Pfeffer, F. Mampaso, D. Schlondorff & B. Luckow: Chemokine receptor CCR2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J. Am. Soc. Nephrol., 16, 3592-3601 (2005)
39. Anders, H.-J., E. Belemezova, V. Eis, S. Segerer, V. Vielhauer, G. Perez de Lema, M. Kretzler, C. D. Cohen, M. Frink, R. Horuk, K. L. Hudkins, C. E. Alpers, F. Mampaso & D. Schlondorff: Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas (lpr) mice. J. Am. Soc. Nephrol., 15, 1504-1513 (2004)
40. Inoue, A., H. Hasegawa, M. Kohno, M. R. Ito, M. Terada, Y. Imai, O. Yoshie, M. Nose & S. Fujita: Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum, 52, 1522-1533 (2005)
41. de Lema, G. P., F. J. Lucio-Cazana, A. Molina, B. Luckow, H. Schmid, C. de Wit, V. Moreno-Manzano, B. Banas, F. Mampaso & D. Schlondorff: Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int., 66, 1018-1028 (2004)
42. Shimizu, S., H. Nakashima, K. Karube, K. Ohshima & K. Egashira: Monocyte chemoattractant protein-1 activates a regional Th1 immunoresponse in nephritis of MRL/lpr mice. Clin. Exp. Rheum., 23, 239-242 (2005)
43. Topham, P., V. Csizmadia, D. Soler, D. Hines, C. Gerard, D. I. Salant & W. W. Hancock: Lack of chelmokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J. Clin. Invest., 104, 1549-1557 (1999)
44. Bird, J. E., M. R. Giancarli, T. Kurihara, M. C. Kowala, M. T. Valentine, P. H. Gitlitz, D. G. Pandya, M. H. French & S. K. Durham: Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int., 57, 129-136 (2000)
45. Boring, L., J. Gosling, S. W. Chensue, S. L. Kunkel, R. V. Farese, H. E. Broxmeyer & I. F. Charo: Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest., 100, 2522-2561 (1997)
46. Izikson, L., R. S. Klein, I. F. Charo, H. L. Weiner & A. D. Luster: Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor CCR2. J. Exp. Med., 192, 1075-1080 (2000)
47. Moore, K. J., T. Wada, S. D. Barbee & V. R. Kelley: Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas (lpr) mice. Kidney Int., 53, 1631-1641 (1998)
48. Patole, P. S., H.-J. Grone, S. Segerer, R. Ciubar, E. Belemezova, A. Henger, M. Kretzler, D. Schlondorff & H.J. Anders: Viral double-stranded RNA aggravates lupus nephritis through toll-like receptor 3 on glomerular mesangial cells and antigen presenting cells. J. Am. Soc. Nephrol., 16, 1326-1338 (2005)
49. Pawar, R. D., P. S. Patole, D. Zecher, S. Segerer, M. Kretzler, D. Schlondorff & H.-J. Anders: Toll-like receptor-7 modulates immune complex glomerulonephritis. J. Am. Soc. Nephrol., 17, 141-149 (2006)
50. Anders, H.-J., V. Vielhauer, V. Eis, Y. Linde, M. Kretzler, G. P. de Lema, F. Strutz, S. Bauer, M. Rutz, H. Wagner, H.-J. Grone & D. Schlondorff: Activation of toll-like receptor-9 induce progression of renal disease in MRL-Fas (lpr) mice. FASEB J. (2004)
51. He, X., T. R. Schoeb, A. Panoskaltis-Mortari, K. R. Zinn, R. A. Kesterson, J. Zhang, S. Samuel, M. J. Hicks, M. J. Hickey & D. C. Bullard: Deficiency of P-selectin or P-selectin glycoptrotein ligand-1 leads to accelerated development of glomerulonephritis and increased expression of CC chemokine ligand 2 in lupus-prone mice. J. Immunol., 177, 8748-8756 (2006)
52. Balabanian, K., J. Couderc, L. Bouchet-Delbos, A. Amara, D. Berrebi, A. Foussat, F. Baleux, A. Portier, I. Durand-Gasselin, R. L. Coffman, P. Galanaud, M. Peuchmaur & D. Emilie: Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in muring lupus. J. Immunol., 170, 3392-3400 (2003)
53. Sato, T., S. Ishikawa, K. Akadegawa, T. Ito, H. Yurino, M. Kitabatake, H. Yoneyama & K. Matsushima: Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur. J. Immunol., 34, 3346-3358 (2004)
54. Tucci, M., N. Calvani, H. B. Richards, C. Quatraro & F. Silverstris: The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann. N.Y. Acad. Sci., 1051, 421-432 (2005)
55. Cockwell, P., A. J. Howie, D. Adu & C. O. S. Savage: In situ analysis of C-C chemokine mRNA in human glomerulonephritis. Kidney Int., 54, 827-836 (1998)
56. Wada, T., K. Furuichi, C. Segawa-Takeada, M. Shimizu, N. Sakai, S.-I. Takeda, K. Takasawa, H. Kida, K.I. Kobayashi, N. Mukaida, Y. Ohmoto, K. Matsushima & H. Yokoyama: MIP-1a and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int., 56, 995-1003 (1999)
57. Wada, T., H. Yokoyama, S. Su, N. Mukaida, M. Iwano, K. Dohi, Y. Takahashi, T. Sasaki, K. Furuichi, C. Segawa, Y. Hisada, S. Ohta, K. Takasawa, K. Kobayashi & K. Matushima: Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int., 49, 761-767 (1996)
58. Niemir, Z. I., H. Stein, A. Ciechanowicz, P. Olejniczak, G. Dworacki, E. Ritz, R. Waldherr & S. Czekalski: The in situ expression of interleukin-8 in the normal human kidney and in different morphological forms of glomerulonephritis. Am. J. Kidney Dis., 43, 983-998 (2004)
59. Segerer, S., M. Mack, H. Regele, D. Kerjaschki & D. Schlondorff: Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney Int., 56, 52-64 (1999)
60. Furuichi, K., T. Wada, N. Sakai, Y. Iwata, K. Yoshimoto, M. Shimizu, K. Kobayashi, K. Takasawa, H. Kida, S. I. Takeda, N. Mukaida, K. Matsushima & H. Yokoyama: Distinct expression of CCR1 and CCR5 in glomerular and interstitial lesions of human glomerular diseases. Am. J. Nephrol., 20, 291-299 (2000)
61. Segerer, S., B. Banas, M. Wornle, H. Schmid, C. D. Cohen, M. Kretzler, M. Mack, E. Kiss, P. J. Nelson, D. Schlondorff & H.-J. Grone: CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis. Am. J. Pathol., 164, 635-649 (2004)
62. Segerer, S., Y. Cui, K. L. Hudkins, T. Goodpaster, F. Eitner, M. Mack, D. Schlondorff & C. E. Alpers: Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis. J. Am. Soc. Nephrol., 11, 2231-2242 (2000)
63. Segerer, S., A. Henger, H. Schmid, M. Kretzler, D. Draganovici, U. Barndt, E. Noessner, P. J. Nelson, D. Kerjaschki, D. Schlondorff & H. Regele: Expression of the chemokine receptor CXCR1 in human glomerular diseases. Kidney Int., 69, 1765-1773 (2006)
64. Segerer, S., E. Hughes, K. L. Hudkins, M. Mack, T. Goodpaster & C. E. Alpers: Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int., 62, 488-495 (2002)
65. Rovin, B. H., M. Rumancik, L. Tan & J. Dickerson: Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab. Invest., 71, 536-542 (1994)
66. Wada, T., H. Yokoyama, N. Tomosugi, Y. Hisada, S. Ohta, T. Naito, K.-I. Kobayashi, N. Mukaida & K. Matsushima: Detection of urinary interleukin-8 in glomerular diseases. Kidney Int., 46, 455-460 (1994)
67. Liu, Z. H., S. F. Chen, H. Zhou, H. P. Chen & L. L.S.: Glomerular expression of C-C chemokines in different types of human crescentic glomerulonephritis. Nephrol. Dial. Transplant., 18, 1526-1534 (2003)
68. Bauer, J. W., E. C. Baechler, M. Petri, F. M. Batliwalla, D. Crawford, W. A. Ortmann, K. J. Espe, W. Li, D. D. Patel, P. K. Gregersen & T. W. Behrens: Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Medicine, 3, 2274-2284 (2006)
69. Amoura, Z., C. Combadiere, S. Faure, C. Parizot, M. Miyara, D. Raphael, P. Ghillani, P. Debre, J.-C. Piette & G. Gorochov: Roles of CCR1 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum, 48, 3487-3496 (2003)
70. Narumi, S., T. Takeuchi, Y. Kobayashi & K. Konishi: Serum levels of ifn-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine, 12, 1561-1565 (2000)
71. Okamoto, H., K. Koizumi, H. Yamanaka, T. Saito & N. Kamatani: A role for TARC/CCL17, a CC chemokine, in systemic lupus eruthematosus. J. Rheumatol., 30, 2369-2373 (2003)
72. Peterson, K. S., J.-F. Huang, J. Zhu, V. D. D'Agati, X. Liu, N. Miller, M. G. Erlander, M. R. Jackson & R. J. Winchester: Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest., 113, 1722-1733 (2004)
73. Rovin, B. H., H. Song, D. J. Birmingham, L. A. Hebert, C.-Y. Yu & H. N. Nagaraja: Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol., 16, 467-473 (2005)
74. Noris, M., S. Bernasconi, F. Casiraghi, S. Sozzani, E. Gotti, G. Remuzzi & A. Mantovani: Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab. Invest., 73, 804-809 (1995)
75. Tesar, V., Z. Masek, I. Rychlik, M. Merta, J. Bartunkova, A. Stejskalova, J. Zabka, I. Janatkova, T. Fucikova, C. Dostal & R. Becvar: Cytokines and adhesion molecules in renal vasculitits and lupus nephritis. Nephrol. Dial. Transplant., 13, 1662-1667 (1998)
76. Tsai, C.-Y., T.-H. Wu, C.-L. Yu, J.-Y. Lu & Y.-Y. Tsai: Increased excretions of beta2-micorglobulin, IL-6, and IL-8 and decreased excretion of tamm-horsfall glycoprotein in the urine of patients with active lupus nephritis. Nephron, 85, 207-214 (2000)
77. Rovin, B. H., N. Doe & L. C. Tan: Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am. J. Kid. Dis., 27, 640-646 (1996)
78. Chuluyan, H. E., T. J. Schall, T. Yoshimura & A. C. Issekutz: IL-1 activation of endothelium supports VLA-4 (CD49d/CD29)-mediated monocyte transendothelial migration to C5a, MIP-1a, RANTES, and PAF but inhibits migration to MCP-1: a regulatory role for endothelium-derived MCP-1. J. Leuk. Biol., 58, 71-79 (1995)
79. Vaddi, K., M. Keller & R. C. Newton: The Chemokine Facts Book. Academic Press, San Diego (1997)
80. Schwartz, N., L. Su, L. Burkly, M. Mackay, C. Aranow, M. Kollaros, J. Michaelson, B. H. Rovin & C. Putterman: Urinary TWEAK and the activity of lupus nephritis. J. Autoimmunity, 27, 242-250 (2006)
81. Holcombe, R. F., B. A. Baethge, R. E. Wolfe, K. W. Betzing, R. M. Stewart, V. C. Hall & M. Fukuda: Correlation of serum interleukin-8 and cell surface lysosome-associated membrane protein expression with clinical disease activity in systemic lupus erythematosus. Lupus, 3, 97-102 (1994)
82. Tucci, M., E. V. Barnes, E. S. Sobel, B. P. Croker, M. S. Segal, W. H. Reeves & H. B. Richards: Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum, 50, 1842-1849 (2004)
83. Chan, R. W.-Y., F. M.-M. Lai, E. K.-M. Li, L.-S. Tam, T. Y.-H. Wong, C. Y. K. Szeto, P. K.-T. Li & C.-C. Szeto: Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum, 50, 2882-2890 (2004)
84. Chan, R. W.-Y., F. M.-M. Lai, E. K.-M. Li, L.-S. Tam, K.-M. Chow, P. K.-T. Li & C.-C. Szeto: Messenger RNA expression of RANTES in the urinary sediment of pateints with lupus nephritis. Nephrology, 11, 219-225 (2006)
85. Chan, R. W.-Y., F. M.-M. Lai, E. K.-M. Li, L.-S. Tam, K.-M. Chow, P. K.-T. Li & C.-C. Szeto: The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol. Dial. Transplant. (2006)
86. Avihingsanon, Y., P. Phumesin, T. Benjachat, S. Akkasilpa, V. Kittikowit, K. Praditpornsilpa, J. Wongpiyabavorn, S. Eiam-Ong, T. Hemachudha, K. Tungsanga & N. Hirankarn: Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis. Kidney Int., 69, 747-753 (2006)
87. Rovin, B. H., L. Lu & R. Saxena: A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem. Biophys. Res. Comm., 259, 344-348 (1999)
88. Liao, C.-H., T.-C. Yao, H.-T. Chung, L.-C. See, M.-L. Kuo & J.-L. Huang: Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. J. Rheumatol., 31, 2062-2067 (2004)
89. Aguilar, F., M. F. Gonzalez-Escribano, J. Sanchez-Roman & A. Nunez-Roldan: MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens, 58, 335-338 (2001)
90. Sanchez, E., J. M. Sabio, J. L. Callejas, E. de Ramon, R. Gracia-Portales, F. J. Garcia-Hernandez, J. Jimenez-Alonso, M. F. Gonzalez-Escribano, J. Martin & B. P. Koeleman: Association study of genetic variants of proinflammatory chemokine and cytokine genes in systemic lupus erythematosus. BMC Med. Gene., 7, 2350-2357 (2006)
91. Ye, D. Q., S. G. Yang, X. P. Li, Y. S. Hu, J. Yin, G. Q. Zhang, H. H. Liu, Q. Wang, K. C. Zhang, M. X. Dong & X. J. Zhang: Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus. Arch. Dermatol. Res., 297, 108-113 (2005)
92. Liu, H., D. Chao, E. Nakayama, H. Taguchi, M. Goto, X. Xin, J.-K. Takamatsu, H. Saito, Y. Ishikawa, T. Akaza, T. Juji, Y. Takebe, T. Ohishi, K. Fukutake, Y. Maruyama, S. Yashiki, S. Sonoda, T. Nakamura, Y. Nagai, A. Iwamoto & T. Shioda: Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. USA, 96, 4581-4585 (1999)
93. Aguilar, F., A. Nunez-Roldan, B. Torres, I. Wichmann, J. Sanchez-Roman & M. F. Gonzalez-Escribano: Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. J. Rheumatol., 30, 1770-1774 (2003)
94. Fischereder, M., B. Luckow, B. Hocher, R. P. Wutrich, U. Rothenpieler, H. Schneeberger, U. Panzer, R. A. K. Stahl, I. A. Hauser, K. Budde, H. Neumayer, B. K. Kramer, W. Land & D. Schlondorff: CC chemokine receptor 5 and renal-transplant survival. Lancet, 367, 1758-1761 (2001)
95. Abdi, R., T. T. B. Huong, A. Sahagun-Ruiz, P. M. Murphy, B. M. Brenner, E. L. Milford & D. H. McDermott: Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J. Am. Soc. Nephrol., 13, 754-758 (2002)
96. Gonzalez, E., B. H. Rovin, L. Sen, G. Cooke, R. Dhanda, S. Mummidi, H. Kulkarni, M. Bamshad, V. Telles, S. A. Anderson, E. A. Walter, K. T. Stephan, M. Deucher, A. Mangano, R. Bologna, S. S. Ahuja, M. J. Dolan & S. K. Ahuja: HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc. Natl. Acad. Sci. USA, 99, 13795-13800 (2002)
97. Rovin, B. H., L. Lu & X. Zhang: A novel interleukin-8 polymorphism is associated with severe SLE nephritis. Kidney Int., 62, 261-265 (2002)
98. Gharaee-Kermani, M., E. M. Denholm & S. H. Phan: Costimulation of fibroblast collagen and transforming growth factor B1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J. Biol. Chem., 271, 17779-17784 (1996)
99. Sakai, N., T. Wada, K. Furuichi, K. Shimizu, S. Kokubo, A. Hara, J. Yamahana, T. Okumura, K. Matsushima, H. Yokoyama & S. Kaneko: MCP-1/CCL2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. J. Leuk. Biol., 79, 555-563 (2006)
100. Jiang, D., J. Liang, J. Hodge, B. Lu, Z. Zhu, S. Yu, J. Fan, Y. Gao, Z. Yin, R. Homer, C. Gerard & P. W. Noble: Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J. Clin. Invest., 114, 291-299 (2004)
101. Frangogiannis, N. G.: Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm. Res., 53, 585-595 (2004)
102. Romagnani, P., C. Beltrame, F. Annunziato, L. Lasagni, M. Luconi, G. Galli, L. Cosmi, E. Maggi, M. Salvadori, C. Pupilli & M. Serio: Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J. Am. Soc. Nephrol., 10, 2518-2526 (1999)
103. Savill, J.: Regulation of glomerular cell number by apoptosis. Kidney Int., 56, 1216-1222 (1999)
104. Schocklmann, H. O., S. Lang & R. B. Sterzel: Regulation of mesangial cell proliferation. Kidney Int., 56, 1199-1207 (1999)
105. Fukushima, M.: Biological activities and mechanisms of action of PGJ2 and related compounds: an Update. Prost. Leuk. Essential Fatty Acids, 47, 1-12 (1992)
106. Reilly, C. M., J. C. Oates, J. A. Cook, J. D. Morrow, P. V. Halushka & G. S. Gilkeson: Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor gamma agonists. J. Immunol., 164, 1498-1504 (2000)
107. Hirata, Y., H. Hayashi, S. Ito, Y. Kikawa, M. Ishibashi, M. Sudo, H. Miyazaki, M. Fukushima, S. Narumiya & O. Hayaishi: Occurrence of 9-deoxy-delta 9, 12-13, 14-dihydorprostaglandin D2 in human urine. J. Biol. Chem., 263, 16619-16625 (1988)
108. Rovin, B. H., J. A. Dickerson, L. C. Tan & C. A. Hebert: Activation of nuclear factor-kappaB correlates with MCP-1 expression by human mesangial cells. Kidney Int., 48, 1263-1271 (1995)
109. Rossi, A., P. Kapahl, G. Natoli, T. Takahashi, Y. Chen, M. Karin & M. G. Santoro: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I kappa B kinase. Nature, 403, 103-108 (2000)
110. Straus, D. S., G. Pascual, M. Li, J. S. Welch, M. Ricote, C.-H. Hsiang, L. L. Sengchanthalangsy, G. Ghosh & C. K. Glass: 15-deoxy-delta 12, 14-prostaglandin J2 inhibits multiple steps in the NF-kappaB signaling pathway. Proc. Natl. Acad. Sci. USA, 97, 4844-4849 (2000)
111. Bishop-Bailey, D.: Peroxisome proliferator-activated receptors in the cardiovascular system. Brit. J. Pharm., 129, 823-834 (2000)
112. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly & C. K. Glass: The peroxisome proliferator-activate receptor-gamma is a negative regulator of macrophage activation. Nature, 391, 79-81 (1998)
113. Ricote, M., J. T. Huang, J. S. Welch & C. K. Glass: The peroxisome proliferator-activated receptor gamma as a regulator of monocyte/macrophage function. J. Leuk. Biol., 66, 733-739 (1999)
114. Chinetti, G., S. Griglio, M. Antonucci, I. P. Torra, P. Delerive, Z. Majd, J.-C. Fruchart, J. Chapman, J. Najib & B. Staels: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem., 273, 25573-25580 (1998)
115. Jiang, C., A. T. Ting & B. Seed: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 391, 82-86 (1998)
116. Rovin, B. H., L. Lu & A. M. Cosio: Cyclopentenone prostaglandins inhibit cytokine-induced NF-kappaB activation and chemokine production by human mesangial cells. J. Am. Soc. Nephrol., 12, 1659-1667 (2001)
117. Zhang, X., J. M. Wang, W. H. Gong, N. Mukaida & H. A. Young: Differential regulation of chemokine gene expression by 15-deoxy-delta12, 14 prostaglanding J2. J. Immunol., 166, 7104-7111 (2001)
118. Jozkowicz, A., J. Dulak, M. Prager, J. Nanobashvili, A. Nigisch, B. Winter, G. Weigel & I. Huk: Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPARgamma-independent manner. Prostaglandins and other Lipid Mediators, 66, 165-177 (2001)
119. Fu, Y., N. Luo & M. F. Lopes-Virella: Upregulation of interleukin-8 expression by protaglandin D2 metabolite 15-deoxy-delta 12, 14 prostaglandin J2 (15d-PGJ2) n human THP-1 macrophages. Atherosclerosis, 160, 11-20 (2002)
120. Zhang, X., L. Lu, C. Dixon, W. Wilmer, H. Song, X. Chen & B. H. Rovin: Stress protein activation by the cyclopentenone prostaglandin 15-deoxy-delta (12, 14)-prostaglandin J2 in human mesangial cells. Kidney Int., 65, 798-810 (2004)
121. Chen, X.-L. & C. Kunsch: Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: A new therapeutic approach for the treatment of inflammatory diseases. Curr. Pharm. Design, 10, 879-891 (2004)
122. Zipper, L. M. & R. T. Mulcahy: Inhibition of ERK and p38 MAP kinases inhibits binding of NrF2 and induction of GCS genes. Biochem. Biophys. Res. Comm., 278, 484-492 (2000)
123. Erickson, A. M., Z. Neverea & J. J. Gipp: Identification of a variant antioxidant response element in the promoter of the human glutamate-cysteine ligase modifer subunit gene: Revision of the ARE consensus sequence. J. Biol. Chem., 277, 30730-30737 (Mulcahy, R.T.)
124. Wild, A. C., H. R. Moinova & R. T. Mulcahy: Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor NrF2. J. Biol. Chem., 274, 33627-33536 (1999)
125. Cho, H.-Y., A. E. Jedlicka, S. P. Reddy, T. W. Kensler, M. Yamamoto, L. Y. Zhang & S. R. Kleeberger: Role of NRF2 in protection against hyperoxic lung injury in mice. Am. J. Respir. Cell. Mol. Biol., 26, 175-182 (2002)
126. Cho, H.-Y., S. P. M. Reddy, M. Yammamoto & S. R. Kleeberger: The transcription factor Nrf2 protects against pulmonary fibrosis. FASEB J., in press, (2004)
127. Braun, S., C. Hanselmann, M. G. Gassmann, U. auf dem Keller, C. Born-Berclaz, K. Chan, Y. W. Kan & S. Werner: Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol. Cell. Biol., 22, 5492-5405 (2002)
128. Yoh, K., K. Itoh, A. Enamoto, A. Hirayama, N. Yamaguchi, M. Kobayashi, N. Morito, A. Koyama, M. Yamamoto & S. Takahashi: Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int., 50, 1343-1353 (2001)
129. Li, J., T. D. Stein & J. A. Johnson: Genetic dissection of systemic autoimmune disease in Nrf2 deficient mice. Physiol. Genomics, 18, 261-272 (2004)
130. Chen, X.-L., G. Dodd, S. Thomas, X. Zhang, M. A. Wasserman, B. H. Rovin & C. Kunsch: Activation of the Nrf2/antioxidant response element pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression: A novel vascular protective pathway. Am. J. Physiol. Heart Circ. Physiol, 290, H1862-H1870 (2006)
131. Zhang, X., X. Chen, H. Song, H.-Z. Chen & B. H. Rovin: Activation of the Nrf2/antioxidant response pathway increases IL-8 expression. Eur. J. Immunol., 35, 3258-3267 (2005)
132. Gimbrone, M. A., M. S. Obin, A. F. Brock, E. A. Luis, P. E. Hass, C. A. Hebert, Y. K. Yip, D. W. Leung, D. G. Lowe, W. J. Kohr, W. C. Darbonne, K. B. Bechtol & J. B. Baker: Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Sci., 246, 1601-1603 (1989)
133. Hechtman, D. H., M. I. Cybulsky, H. J. Fuchs, J. B. Baker & M. A. Gimbrone: Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J. Immunol., 147, 883-892 (1991)
134. Simonet, W. S., T. M. Hughes, H. Q. Nguyen, L. D. Trebasky, D. M. Danilenko & E. S. Medlock: Long-term impaired neutrophil migration in mice overexpressing human interleukin-8. J. Clin. Invest., 94, 1310-1319 (1994)
135. Ley, K., J. B. Baker, M. I. Cybulsky, M. A. Gimbrone & F. W. Luscinskas: Intravenous interleukin-8 inhibits granulocyte emigration from rabbit mesenteric venules without altering L-selectin expression or leukocyte rolling. J. Immunol., 151, 6347-6357 (1993)
136. Rennekampff, H.-O., J. F. Hansbrough, V. Kiessig, C. Dore, M. Sticherling & J.-M. Schroder: Bioactive interleukin-8 is expressed in wounds and enhances wound healing. J. Surg. Res., 93, 41-54 (2000)
137. Li, A., S. Dubey, M. L. Varney, B. J. Dave & R. K. Singh: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol., 170, 3369-3376 (2003)
138. Lefer, A. M., G. Johnson, X. L. Ma, P. S. Tsao & G. R. Thomas: Cardioprotective and endothelial protective effects of [Ala-IL8] 77 in a rabbit model of myocardial ischaemia and reperfusion. Br. J. Pharmacol., 103, 1153-1159 (1991)
139. Marsh, C. B., J. E. Gadek, G. C. Kindt, S. A. Moore & M. D. Wewers: Monocyte Fc gamma receptor crosslinking induces interleukin-8 production. J. Immunol., 155, 3161-3167 (1995)
140. Hsieh, S. C., C. Y. Tsai, K. H. Sun, H. S. Yu, S. T. Tsai, J. C. Wang, Y. Y. Tsai, S. H. Han & C. L. Yu: Decreased spontaneous and lipopolysaccharide stimulated production of interleukin 8 by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Clin. Exp. Rheumatol., 12, 627-633 (1994)
141. Rovin, B. H., H. Song, L. A. Hebert, T. Nadasdy, G. Nadasdy, D. J. Birmingham, C. Y. Yu & H. N. Nagaraja: Plasma, urine, and renal expresssion of adiponectin in human systemic lupus erythematosus. Kidney Int., 68, 1825-1833 (2005)
142. Maeda, K., K. Okubo, I. Shimomura, T. Funahashi, Y. Matsuzawa & K. Matsubara: cDNA cloning and expression of a novel adipose specifice collagen-like factor, apM1. Biochem. Biophys. Res. Comm., 221, 286-289 (1996)
143. Diez, J. J. & P. Iglesias: The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endo., 148, 293-300 (2003)
144. Yamauchi, T., J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M. L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Forguel & T. Kadowaki: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 7, 941-946 (2001)
145. Berg, A. H., T. P. Combs, X. Du, M. Brownlee & P. E. Scherer: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med., 7, 947-953 (2001)
146. Ouchi, N., S. Kihara, Y. Arita, K. Maeda, H. Kuriyama, Y. Okamoto, K. Hotta, M. Nishida, M. Takahashi, T. Nakamura, S. Yamashita, T. Funahashi & Y. Matsuzawa: Novel modulator for endothelial adhesion molecules. Circ., 100, 2473-2476 (1999)
147. Kawanami, D., K. Maemura, N. Takeda, T. Harada, T. Nojiri, Y. Imai, I. Manabe, K. Utsunomiya & R. Nagai: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem. Biophys. Res. Comm., 314, 415-419 (2004)
148. Wulster-Radcliffe, M. C., K. M. Ajuwon, J. Wang, J. A. Christian & M. E. Spurlock: Adiponectin differentially regulates cytokines in procine macrophages. Biochem. Biophys. Res. Comm., 316, 924-929 (2004)
149. Kumada, M., S. Kihara, O. Noriyuki, H. Kobayashi, Y. Okamoto, K. Ohashi, K. Maeda, H. Nagarentani, K. Kishida, N. Maeda, A. Nagasawa, T. Funahashi & Y. Matsuzawa: Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circ., 109, 2046-2049 (2004)
150. Rovin, B. H. & H. Song: Chemokine induction by the adipocyte-derived cytokine adiponectin. Clin. Immunol., 120, 99-105 (2006)
151. Saijo, S., K. Nagata, Y. Nakano, T. Tobe & Y. Kobayashi: Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem Biophys Res Comm, 334, 1180-1183 (2005)
152. Lappas, M., M. Permezel & G. E. Rice: Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kB, peroxisomal proliferator-activated receptor-gamma, and extracellularly regulated kinase 1/2. Endocrinology, 146, 3334-3343 (2005)
153. Chen, T.-H., L. Chen, M.-S. Hsieh, C.-P. Chang, D.T. Chou & S.-H. Tsai: Evidence for a protective role for adiponectin in osteoarthritis. Biochimica et Biophysica Acta, in press, (2006)
154. Ehling, A., A. Schaffler, H. Herfarth, I. H. Tarner, S. Anders, O. Distler, G. Paul, J. Distler, S. Gay, J. Scholmerich, E. Neumann & U. Muller-Ladner: The potential of adiponectin in driving arthritis. J. Immunol., 176, 4468-4478 (2006)
155. Neumeier, M., J. Weigert, A. Schaffler, G. Wehrwein, U. Muller-Ladner, J. Scholmerich, C. Wrede & C. Buechler: Different effects of adiponectin isoforms in human moncytic cells. J. Leuk. Biol., 79, 803-808 (2006)
156. Tsao, T.-S., E. Tomas, H. E. Murrey, C. Hug, D. H. Lee, N. B. Ruderman, J. E. Heuser & H. F. Lodish: Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. J. Biol. Chem., 278, 50810-50817 (2003)
157. Tsao, T.-S., H. E. Murrey, C. Hug, D. H. Lee & H. F. Lodish: Oligomerization state-dependent activation of NFkB signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J. Biol. Chem., 277, 29359-29362 (2002)